Acute Myeloid Leukemia
As BIO 2021 Approaches, Taiwan’s DCB Reveals Competitive Bio-Innovations to Watch Out For
2021-06-11
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
Bristol Myers Squibb Notches Key Regulatory Win for Oral Formulation of Epigenetic Modifier
2020-09-06
Bristol-Myers-Squibb Anticipates FDA Approval for CC-486 as a Treatment for Acute Myeloid Leukemia
2020-08-30
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115